Professor Judith Bliss is Director of the Cancer Research UK funded Clinical Trials and Statistics Unit (ICR-CTSU) and Deputy Head of the Division of Clinical Studies. She is a trial methodologist with interests in both cancer clinical trials design and analysis, particularly in striving to ensure the contemporary trials are sufficiently robust to provide both the safety and efficacy results required to directly influence routine clinical practice.
The focus of her more recent work involves trials aimed at maximising benefit in the treatment of breast cancer. This includes work comparing different chemotherapeutic agents and different radiotherapy schedules as well as optimising the scheduling of endocrine therapy and seeking early evidence of biological activity of novel agents especially through a suite or perioperative window of opportunity trials. She collaborates with clinical coordinators and investigators located in many countries throughout Europe and elsewhere, including via the Breast International Group. She is actively engaged in research relating to the challenges associated with capturing long term follow up and accessing routinely collected data to obtain outcome data for trial patients.
Professionally trained as a medical statistician (MSc in Medical Statistics & Information Technology from the University of Leicester and Fellow of the UK Royal Statistical Society), her statistical and trial management contribution to clinical trials, particularly in breast cancer, was recognised in 2006 with the conferment of the title of Professor in Clinical Trials (University of London). As a member of the Executive Group of the UK National Cancer Research Institute (NCRI) and registered by UK Clinical Research Collaboration (UKCRC) Clinical Trials Units Network and Chair of the NCRI Cancer CTU Group she is actively involved in the strategic development of the clinical trials research framework in the UK.
She is a member of the (NCRI) Breast Clinical Studies Group and chair of its Early Disease Subgroup and UK Breast Intergroup. Internationally, she is a member of the Steering Committee for the Early Breast Cancer Trialists Collaborative Group (EBCTCG) and an active member of the Aromatase Inhibitor Overview Group (AIOG).